Thomson Reuters Launches Asthma Disease Partnership Program

Tue Feb 26, 2013 8:30am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

Company works with leading pharmaceutical organizations to advance asthma research

PHILADELPHIA, February 26, 2013 - The Intellectual Property & Science business  of Thomson Reuters, the world's leading provider of
intelligent information for businesses and professionals, today announced the launch of
MetaMiner(TM) Asthma, the latest industry-academic-government, disease-focused collaboration
dedicated to advancing the understanding of pathological pathways that cause asthma and the
development of novel patient profiling methods to improve the diagnosis and treatment for
asthmatic patients.

"Thomson Reuters is delighted to announce its MetaMiner Asthma Partnership program, bridging two
of the top 10 pharmaceutical companies with academic and government excellence in asthma disease
understanding and treatment", said Jon Brett-Harris, managing director of Life Sciences at Thomson
Reuters. "This program creates a venue for participating organizations to collaborate together and
with the Thomson Reuters team of systems biology experts in the curation of disease pathways and
development of computational methods to advance treatments for asthmatics."

MetaMiner Asthma will provide unique insight into the pathological mechanisms underlying asthma,
including the different cell types involved in the disease. The result of this partnership will
add to the currently available collection of respiratory maps by producing over 30 new pathway
maps related to the signaling of immune cells involved in asthma pathology, such as T-cells,
macrophages, eosinophils and neutrophils. These maps and the insights from computational analyses
using the pathways will be exclusively available to participating members for the first year, in
order to aid in asthma research and protect intellectual property interests.

The asthma pathway maps will be delivered via MetaCore(TM), the world's most comprehensive,
knowledge-based platform for data mining and functional biology-related analysis. The content can
be used for target discovery, candidate selection, biomarker discovery, translational medicine and
personalized care applications. 

MetaMiner Asthma is the most recent phase of the MetaMiner Respiratory Disease program, which also
includes MetaMiner COPD (Chronic Obstructive Pulmonary Disease). "MetaMiner Disease Partnerships
for asthma and COPD will result in approximately 150 maps; this is an unprecedented
disease-pathology development that will help industry players, academic researchers, government
policy makers, and payers to develop new diagnostics and treatments for asthma, faster," said Mr.

Learn more about the MetaMiner Disease Partnership

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and
professionals. We combine industry expertise with innovative technology to deliver critical
information to leading decision makers in the financial and risk, legal, tax and accounting,
intellectual property and science and media markets, powered by the world's most trusted news
organization. With headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more
information, go to


Jen Breen
Thomson Reuters 
+1 215 823 1791

Abbey Anderson
Thomson Reuters 
+ 1 215 823 1894


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Thomson Reuters Corporation via Thomson Reuters ONE


Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.